In 2006, Genentech re-entered into the neuroscience fray by partnering with AC Immune to develop novel Alzheimer disease treatments. A year and half later, Morgan Sheng joined the biotech firm as Vice President of Neuroscience, and was tasked with putting together a plan to eke new drug candidates out of emerging science. Ten years on, the firm's neuroscience pipeline includes three Alzheimer drugs, one amyotrophic lateral sclerosis drug, one pain drug and a number of preclinical candidates. Sheng spoke with Asher Mullard about his continued faith in the amyloid hypothesis, the case for novel Alzheimer disease targets, the promise of emerging Parkinson disease genetics and the overlap between psychiatric disease and neurodegeneration.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Morgan Sheng. Nat Rev Drug Discov 17, 88–89 (2018). https://doi.org/10.1038/nrd.2017.271
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.271